What Clearmind Biomedical does

ClearMind Biomedical Inc. is a privately held medical device company founded in 2014 with backing from Y Combinator and origins in the Stanford-Taiwan Biomedical Fellowship Program. The company develops and commercializes minimally invasive neurosurgical endoscopy systems for the treatment of intracerebral hemorrhage (ICH), the deadliest form of stroke with reported death rates of 36-60%. Its core technology is a 6.5mm access channel micro-invasive platform that consolidates visualization, illumination, irrigation, suction, coagulation, and powered debridement into single-use neuroendoscope handpieces controlled via reusable high-definition touchscreen monitors.

The product portfolio centers on two generations of the platform. The Axonpen System, FDA 510(k) cleared in the US in 2020 and in Taiwan in 2021, is the first generation multifunctional neuroendoscope with a bendable tip. The Neuroblade System, FDA 510(k) cleared in August 2024, is the second-generation all-in-one device combining bipolar coagulation, morcellator debridement, lens cleaning, suction, and irrigation and is composed of the disposable Neuroblade endoscope, the reusable 15-inch Neuropad touchscreen monitor, and the disposable Clearpath transparent access sheath that integrates with optical and electromagnetic surgical navigation systems. The company has filed 21 patents supporting the Neuroblade platform.

ClearMind operates from dual headquarters in San Jose, California (US) and New Taipei City, Taiwan, employing 11-50 staff across both locations. Its revenue model is enterprise medical device sales of hardware plus disposables, distributed via direct hospital sales targeting neurosurgery departments, with named clinical reference sites at Mt. Sinai Hospital in New York (first US Neuroblade surgery, Dr. Christopher Kellner) and Chang Gang Memorial Hospital in Taiwan (FIM clinical trial site). The company has completed seed, Series A (2017), and Series B (2022, including Darwin Venture Management) funding rounds, leadership comprises CEO Carrey Yang, CTO/CFO Paul Chan, VP & GM Americas J. Dustin Duckett, and BD Manager Penny Huang, and the company pursues a stated objective of enabling a single surgeon to complete ICH procedures in one hour at regional hospitals.

Name

Clearmind Biomedical

Legal name

ClearMind Biomedical Inc.

Website

https://clearmindbiomedicalgroup.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

ClearMind Biomedical is a privately held medical device company that develops minimally invasive neurosurgical endoscopy systems for treating intracerebral hemorrhage (hemorrhagic stroke), combining visualization, suction, irrigation, coagulation, and debridement into single-use devices sold to hospital neurosurgery departments in the US and Taiwan.

Ownership category

akta.pro rank

Product category

Neurosurgical Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)

akta.pro secondary industries

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL)

Keywords

• Neurosurgical endoscopy systems
• Minimally invasive neurosurgery
• Intracerebral hemorrhage treatment
• Neuroendoscopic medical devices
• Hemorrhagic stroke devices

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Neuroblade System Sales: Sale of the Neuroblade System comprising disposable components (Neuroblade endoscope, Clearpath sheath) and reusable hardware (Neuropad monitor). Medical device capital and consumables model.
2. Axonpen System Sales: Sale of Axonpen System including disposable endoscope components and reusable monitor (Axon Monitor).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Clearmind Biomedical manufactures and sells micro-invasive neurosurgical endoscopy systems used by neurosurgeons in hospitals to treat intracerebral hemorrhage (ICH) and brain hemorrhage. The product portfolio centers on two FDA 510(k)-cleared platforms - the Axonpen System (multifunctional neuroendoscope with bendable tip and 6.5mm access) and the Neuroblade System (an all-in-one disposable neuroendoscope integrating visualization, illumination, irrigation, suction, coagulation, and powered debridement, used with a reusable touchscreen monitor and disposable access sheath). Devices are sold to hospital neurosurgery departments via direct sales and procurement.

Product overview

Clearmind Biomedical is a medical device company offering a portfolio of minimally invasive neurosurgical systems for the treatment of intracerebral hemorrhage (ICH) and brain hemorrhage. The portfolio consists of two primary product platforms — the Axonpen System and the Neuroblade System — both designed around the company's proprietary micro-invasive technology to enable least-invasive brain surgery. The Axonpen System is a multifunctional endoscope combining visualization, suction, irrigation, and a bendable tip with its companion Axon Monitor, suited for ICH and subdural hematoma procedures. The Neuroblade System is a newer-generation all-in-one platform comprising three components: the Neuroblade single-use neuroendoscope (with integrated coagulation, debridement, suction, and irrigation), the Neuropad reusable touchscreen tablet interface, and the Clearpath disposable transparent access sheath (which also integrates with optical and EM surgical navigation systems). Both platforms target the same clinical indication — ICH evacuation — with a stated objective of enabling a single surgeon to complete procedures in one hour at regional hospitals.

Differentiator

Problem solved

Functional benefit

Brands

• Axonpen System: Multifunctional neuroendoscope for ICH treatment with disposable endoscope, coagulation system integration, debrider, suction/irrigation, and bendable tip. Features high definition visualization with Axon Monitor.
• Neuroblade System
• Clearpath

Products and services

• Axonpen System A multifunctional neurosurgical endoscope system for the treatment of intracerebral hemorrhage (ICH) and subdural hematomas, combining tissue visualization, suction, irrigation, and a bendable tip into a single minimally invasive operating platform. Requires only a 6.5mm skull channel for brain access, integrates with coagulation systems and homeostasis applicators, and includes the Axon Monitor for high-definition visualization and intraoperative screenshot capture. Targeted at neurosurgery departments in hospitals.
• Neuroblade System An all-in-one, single-use multifunctional neuroendoscopic system for minimally invasive ICH surgery, integrating bipolar coagulation, morcellator debrider, lens cleaning technology, suction, and irrigation into a single handpiece. The platform comprises three components: Neuroblade (disposable endoscope), Neuropad (reusable 15-inch high-definition touchscreen monitor), and Clearpath (disposable transparent access sheath). FDA 510(k) cleared in 2024 for use by neurosurgeons in hospitals.

Quantifiable outcome

• 5% mortality rate (vs 35-50% traditional)
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Partnerships

One partnership is on record.

• Stanford-Taiwan Biomedical Fellowship ProgramfoundationalStrategic or Co-development PartnerClearMind founders were members of the Stanford-Taiwan Biomedical Fellowship Program, which inspired them to create the company and develop their medical device innovations.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Nico Corporation: Nico is a direct competitor in minimally invasive brain surgery with its BrainPath system for ICH and tumor evacuation. Both companies target the same neurosurgery use case (minimally invasive access to deep brain lesions) with single-use access and evacuation devices sold to neurosurgery departments.
• Penumbra: Penumbra operates in the neurovascular and neurosurgery space with aspiration and access systems used in stroke and ICH procedures. Clearmind competes with Penumbra's Apollo and other systems targeting the same neurosurgeon buyer in hospitals performing hemorrhagic stroke interventions.

Broad incumbents

• Integra LifeSciences: Integra is a diversified neurosurgery incumbent offering a broad portfolio of instruments, dural repair products, and surgical devices. It overlaps with Clearmind in neurosurgery OR workflows and competes for hospital neurosurgery budgets, although it does not have a directly integrated ICH evacuation platform.
• Medtronic: Medtronic has a broad neurosurgery and neurovascular portfolio including cranial, spinal, and surgical instrument lines. As a large incumbent, it competes with Clearmind for hospital neurosurgery capital and consumable spend, and could leverage scale to enter integrated ICH evacuation if the market proves attractive.
• Stryker: Stryker's neurosurgery and surgical instruments division sells instruments and visualization tools to neurosurgery departments. While it does not directly compete with Clearmind's integrated ICH device, it competes for the same hospital budget and surgeon relationship.
• Karl Storz: Karl Storz is a leading endoscopy systems vendor with neuroendoscopy and visualization offerings. As an incumbent endoscopy player, it overlaps with Clearmind on visualization hardware and consumables in neurosurgery, though it has not historically focused on integrated ICH evacuation.
• Olympus: Olympus is a global endoscopy leader with surgical endoscopy systems used across specialties including neurosurgery. It is an incumbent in visualization and endoscopic instrumentation but does not currently market a directly integrated ICH evacuation system comparable to Neuroblade.

Emerging players

• Brainlab: Brainlab provides surgical navigation and planning software that integrates with neurosurgical workflows. Clearmind's Clearpath is designed to integrate with optical and EM navigation systems such as Brainlab's, making Brainlab a complementary/adjacent player rather than a direct device competitor.
• Viz.ai: Viz.ai is an AI-powered stroke imaging and workflow company that routes suspected stroke patients (including ICH) to appropriate hospitals. It is adjacent rather than directly competitive, but it sits in the same hemorrhagic stroke care pathway and influences which surgeons and hospitals Clearmind can target.
• RapidAI: RapidAI provides AI-driven imaging and workflow tools for stroke (ischemic and hemorrhagic). Like Viz.ai, it is adjacent to Clearmind in the hemorrhagic stroke care continuum, helping hospitals identify and triage ICH patients who may become candidates for Clearmind's evacuation systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@Clearmind-Bio
• LinkedInlinkedin.com/company/clearmind-biomedical-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clearmind Biomedical